Monoclonal antibodies directed against tumour necrosis factor-α (anti-TNF) have conventionally been the cornerstone of the treatment of moderate-to-severe inflammatory bowel disease (IBD) [1]. This evidence concerns the gene TNF and inflammatory bowel disease.